• Marijuana sales in Michigan hit record $115.4 million in March, more than twofold increase over March 2020
• U.S. marijuana markets forecasted to reach an estimated $45.9 billion in annual sales by 2025
• HENC focused on developing “largest vertically integrated cannabis company the world has ever known”

The numbers being reported in Michigan’s cannabis space are impressive, and companies operating in the state, such as Hero Technologies (OTC: HENC), are watching the growth of the industry closely. The state’s numbers should only increase as the cannabis market in the United States hits record highs. “Recreational and medical marijuana sales in the state hit a record $115.4 million in March, a more than two-fold increase over March 2020, according to Headset, a company that analyzes cannabis consumer trends,” reported a recent Detroit Metro Times article (https://ibn.fm/lsVMA). “There were 1.4 million transactions in March.” The article also noted that in 2020, the first full year of legal recreational sales, Michigan dispensaries reported more than $500 million in purchases, with sales declining slightly late last year. “But in early 2021, sales not only rebounded, they began to soar to record levels,” the article continued. “That growth is expected to continue.” The most recent Marijuana Business Factbook reports that “the U.S. recreational and medical marijuana markets are on a trajectory to reach up to $45.9 billion in annual sales by 2025, or as much as twice the level of sales projected for this year. . . . U.S. adult-use and medical cannabis sales in 2021 are expected to reach $22 billion–$26.4 billion” (https://ibn.fm/TcwcF). With U.S. and Michigan numbers heading skyward, Hero Technologies appears to be ideally positioned in the burgeoning market. “We are growers and cultivators, developers, builders, engineers, marketers, and managers all here to serve Hero Technologies Inc. as we rapidly develop the largest vertically integrated cannabis company the world has ever known,” proclaims the company website (https://ibn.fm/uTNor). And while that statement may seem lofty, a closer look at the company reveals a portfolio of companies that provide superior cultivation and dispensary assets. HENC’s portfolio includes a majority stake in BlackBox Systems and Technologies LLC., an aeroponic cannabis cultivation system that provides optimal conditions to enhance photosynthesis and cultivation of large flowering plants, creating increased efficiencies. Hero Technologies is planning expansion of cultivation and dispensary operations into Massachusetts through wholly owned subsidiary MassCannabis LLC. In addition, Hero Technologies owns and operates two hemp websites: HighlyRelaxing.com under Highly Relaxing LLC and VeteranHempCo.com. Hero Technologies Inc. is a cannabis company working toward a vertically integrated business model. The company’s strategic business plan includes cannabis genetic engineering, farmland for both medical and recreational cannabis cultivation, production licenses, distribution licenses, consumer packaging, and retail and dispensary operations that make the company a multistate operator. For more information, visit the company’s website at www.HeroTechnologiesInc.com. NOTE TO INVESTORS: The latest news and updates relating to HENC are available in the company’s newsroom at https://ibn.fm/HENC

• FingerMotion Inc. reported total annual revenue of $16.68 million for the 2021 financial year ended February 28, 2021
• This FYE 2021 results represented an 82% growth from the FYE 2020 results
• The company also posted $2.11 million in positive shareholders’ equity
• The growth was attributed to an increase in subscriber numbers, resource optimization, and the mix between Top-up and SMS product and service offerings

Founded in 2016 as a mobile gaming enterprise, FingerMotion (OTCQX: FNGR) has become a leading mobile services and data company. In the 2021 financial year, FingerMotion, Inc posted its highest revenue and year-over-year revenue growth thus far, as indicated in its reports for the fiscal year ending February 28, 2021. According to the press release (https://ibn.fm/Wss7I) dated June 2, 2021, FingerMotion Inc. reported annual revenue of $16.68 million, an 82% growth from the previous financial year 2020. Its SMS and MMS segment posted business revenue of $6.13 million for the 2021 fiscal year, an 84% growth from the year prior. This growth showed the company’s commitment to innovation and streamlining its operations for the overall development of the enterprise. FingerMotion Inc.’s fourth quarter for the 2021 fiscal year generated revenue totaling $5.43 million in its third consecutive quarter of record revenue. “The company recently announced that Top-up revenue could increase by as much as 1000% and that SMS revenue could increase by 20-30% in FYE 2022,” said Shen in a statement accompanying the announcement. The 2021 impressive fiscal performance was mainly attributed to the company’s commitment to growth in its subscribers, a factor that, Mr. Shen noted, will further allow for the increase in revenue for the coming financial year. Additionally, Mr. Shen stated that the company’s resolve to expand into new regions, coupled with fostering solid relationships with other players in the telecommunications industry, is set to guarantee its platform’s reliability and spur customer loyalty. FingerMotion Inc. is also dedicated to research and development. In the 2021 financial year, it spent $0.55 million, a 42% increase from the previous financial year in the research and development of new products for its customers. Going forward, the company seeks to invest in its Big Data Insights division, an investment that will yield multiple contracts relating to its Insuretech line of products.  In the 2021 fiscal year, FingerMotion’s Big Data business reported first revenues of $33,077, with prospects for further growth in the coming financial year. This shows FingerMotion’s pledge to innovation and its overall outlook on the opportunities that currently exist in the market. In terms of profit, FingerMotion ended its 2021 financial year with a 71% growth. Shen attributed this progression to its resource optimization and its delicate mix between Top-up and SMS product and service offerings. He noted, however, that the company’s biggest challenge currently is access to non-dilutive capital. The company’s overall growth for the 2021 financial year was great news for shareholders, having posted $2.11 million in positive shareholders’ equity. “For FingerMotion’s shareholders, this is a big step forward because many senior exchanges require a certain amount of positive shareholders’ equity to qualify under listing standards,” said Martin J. Shen. As the company continues to evolve and innovate, the future looks bright for FingerMotion Inc. The 2022 financial year continues to develop additional value-added technologies to appeal more to its users. The company’s overall vision is to rapidly yet organically grow the user base and have this growth morph into an ecosystem of users with high engagement rates utilizing its innovative applications. Every segment of FingerMotion Inc’s offerings feeds into the other. The company hopes this is the ecosystem that will eventually serve over 1 billion users, starting with the Chinese market before finally expanding to other regional markets. For more information, visit the company’s website at www.FingerMotion.com. NOTE TO INVESTORS: The latest news and updates relating to FNGR are available in the company’s newsroom at https://ibn.fm/FNGR

Date: June 15-17, 2021 Virtual Event Event Highlights

• The conference aims to ensure compliant pre-market and post-market operations
• The event will feature case studies, panel discussions, and presentations by 15+ industry professionals holding senior positions at various pharmaceutical and biotechnology companies
• Attendees should expect to get their unique needs addressed as the program includes Q&A sessions after every discussion
• There will be 30-minute virtual networking sessions daily

As an organizer whose mission is to propel highly regulated industries forward through platforms of curated executive learning with a focus on quality, Q1 Productions invites you to one such platform: the 7th Annual Global Regulatory Affairs CMC: Chemistry, Manufacturing, and Controls Conference, a virtual event to be held on June 15-17, 2021. The conference aims to ensure compliant pre-market and post-market operations using comprehensive product lifecycle management strategies and strict supply chain change-control processes. In this regard, it will explore the evolution of products throughout their lifecycle and discuss guideline changes, as well as the challenges emanating from global regulatory harmonization. Designed to better equip CMC teams with knowledge on how to deliver uninterrupted product supply chains, streamline approval processes, and showcase products’ efficacy, quality, and chemical makeup in an evidence-based manner, the virtual conference will feature case studies, panel discussions, and presentations, all facilitated by industry professionals. To maximize knowledge acquisition and engagement, the learning will be delivered in three half-day modules scheduled from 9:30 am to 1:15 pm CST. Module 1 will have nine facilitators holding executive positions at various pharmaceutical and biotechnology companies wherein they oversee regulatory affairs or CMC operations. The conference, to be held on the Q1 Productions virtual event app, will kick off with a keynote panel in which five panelists will examine the topic Navigating the Continually Dynamic CMC Landscape. Day 1 will include three additional presentations and a 30-minute virtual networking session and coffee break. Module 2 will pick up where the facilitators will left on day one by exploring the regulatory approvals in Brazil and China. Like the first day, the second day will also feature a virtual networking session and coffee break, followed by a presentation by the Head, Global Chemistry, Manufacturing & Controls at Merck (NYSE: MRK), Ganapathy Mohan, who will decode the standards related to nitrosamine data requirements. Later, Christina Markus, Deputy Chair, FDA & Life Sciences Practice at King and Spalding, will discuss the CMC development and regulatory considerations for cell and gene therapies, the last presentation of the day. Module 3 will feature two presentations and a session series titled Quality and regulatory requirements for a product’s starting materials, in which presenters Arul Joseph, the Senior Director, Pharmaceutical Development & Clinical Supply Chain at Avanir Pharmaceuticals and Ambarish Singh, the Head of Regulatory CMC at Constellation Pharmaceuticals (NASDAQ: CNST), will each present case studies. Attendees should expect to gain insights and a comprehensive understanding of regulatory affairs in CMC and learn from industry experts with many years’ experience currently holding senior positions in their respective companies. What’s more, attendees will get to customize their experiences and seek answers to their unique concerns and questions during live Q&A sessions after each discussion. They should also anticipate interactive and fun sessions owing to Q1 Productions’ emphasis on using different types of session formats, as well as scheduling virtual networking sessions. With all these characteristics, the event indeed espouses Q1 production’s mantra – Dedicated to Quality First. For more information regarding the event, please visit https://ibn.fm/vpOjH

• Health and wellness CBD-based probiotics distributor HempFusion Wellness, Inc. recently announced an agreement to acquire CBD brand pioneer Apothecanna’s holding company
• The deal will give HempFusion an additional 1,800 retail outlets for its brand, notably in CVS stores, to supplement the 4,000 retail locations HempFusion already uses in all 50 states
• Apothecanna’s sales revenues during 2020 were more than $4 million — double HempFusion’s historical revenue
• HempFusion also recently announced that a multi-billion-dollar customer in Dubai, United Arab Emirates, has revived its product purchases after more than a year’s pause in international sales during the pandemic

Health and wellness supplement innovator HempFusion Wellness (TSX: CBD.U) (OTC: CBDHF) (FWB: 8OO) is expanding its footprint in retail outlets while celebrating the revival of international sales for its cannabidiol (“CBD”) lines. HempFusion has established itself as a scientifically formulated probiotic product retailer that relies on hemp to help specific consumer demographics achieve total gut health support and skin care. On May 17, the company announced it has entered a purchase agreement that will allow it to acquire 100 percent interest in APCNA Holdings LLC, the holdings company that owns the Apothecanna CBD line (https://ibn.fm/vRUtS). Apothecanna is a CBD brand that is distributed in 1,800 stores nationwide through CVS and 7th Sense outlets, as well as others. The opportunity for HempFusion’s brand to increase its distribution by nearly 2,000 stores is augmented by Apothecanna’s strategic business relationship that gives it significant market share in the Canadian topicals space. Apothecanna pioneered cannabis-powered body care and topicals and was the first topicals brand to expand nationally and obtain a federal trademark, according to the news release. Last year it had revenues of over $4 million, which is double HempFusion’s historical revenue and the company has plans to continue expanding during 2021. “We are incredibly excited to enter into this agreement with Apothecanna, which, on closing, will have an immediate impact on HempFusion’s revenue while significantly bolstering our distribution and eCommerce platforms,” HempFusion cofounder and CEO Jason Mitchell, N.D., stated in the announcement. “We look forward to working to close the transaction as soon as possible.” Ecommerce accounts for about 50 percent Apothecanna’s revenues, driving more than 17,000 average monthly sessions, and nearly $2 million in gross sales per year with a 76 percent gross margin. On May 12, HempFusion also announced a recent purchase order for more than $200,000 of its branded products signals the revival of international sales following the difficulties posed by the COVID pandemic for foreign transactions during the past year (https://ibn.fm/Lh7nF). The unnamed multi-billion-dollar distribution company that placed the purchase order has not ordered anything from HempFusion in over a year. Because of the two companies’ historical relationship over most of the last decade, HempFusion had expected the other company, which is based in Dubai, to place orders for $800,000 worth of product in 2020 and $1 million worth of product this year. So HempFusion is “excited to see this early indication that business on a global scale is starting to move in the right direction,” HempFusion Head of International Development Patrick Bucaro stated in the announcement. HempFusion has over a year of working capital and no plans for further financings at this time. Prior to establishing the acquisition agreement with APCNA Holdings, the company stated its products are sold in about 4,000 retail locations in all 50 U.S. states utilizing 45 brokers and sales representatives in the natural products industry and another 55 in the doctor/practitioner market, conventional food, drug, mass and convenience (“FDMC”) market and international markets. HempFusion is also listed in Canada on the Toronto Securities Exchange (“TSX”) and has expectations of entering India, Ireland, and the United Kingdom in the near future. For more information, visit the company’s website at www.HempFusion.com/corporate-information. NOTE TO INVESTORS: The latest news and updates relating to HempFusion are available in the company’s newsroom at https://ibn.fm/CBDHF

• Feasibility study is designed to measure ketamine’s psychedelic effect on cerebral cortex hemodynamics
• Cybin, Kernel working together to leverage proprietary Kernel Flow device for psychedelic-based studies and clinical trials
• Ketamine is a dissociative injected anesthetic that blocks sensory perception

Cybin (NEO: CYBN) (OTCQB: CLXPF) has announced a key step forward in its focus on progressing psychedelic therapeutics. The company will be sponsoring a feasibility study of the Kernel Flow technology; the study is designed to measure ketamine’s psychedelic effect on cerebral cortex hemodynamics (https://ibn.fm/BW1Jn). “We still have much to learn about what is occurring in the brain during a psychedelic experience,” said Cybin CEO Doug Drysdale. “This first-of-its-kind, Cybin-sponsored study using the Kernel Flow device aims to expand our physiological understanding of psychedelic pharmacotherapy. We are excited to be part of this pioneering journey with our partners at Kernel.” Cybin announced a partnership with Kernel earlier this year. The two companies are working together to leverage Kernel’s proprietary Kernel Flow device for psychedelic-based studies and clinical trials. The Kernel Flow device is the first commercially scalable time-domain near-infrared spectroscopy (TD-fNIRS) system in history. The device uses quantitative neuroimaging technology that measures brain activity in real time when users wear the device during psychedelic treatments. According to Cybin, Kernel Flow uses pulsed light to increase measured brain information. In contrast with electroencephalography (“EEG”) electrodes, which typically require gel on the head, or functional magnetic resonance imaging (“fMRI”) studies, which require a participant to lie in a scanner, the Flow device is a wearable helmet. The device has potential for broad use in neuroscientific or physiological studies of brain activity during psychedelic use; little direct neuroimaging research of psychedelic effects, in vivo, have been attempted until now, and that research has never been done with a wearable device. The study will use the device to study ketamine, a dissociative injected anesthetic that blocks sensory perception and has been available by prescription in the United States since the 1970s for human and veterinary uses (https://ibn.fm/uv5Zk). A form of ketamine has been approved for treatment-resistant depression and is approved for use in depressed patients with acute suicidal ideation or behavior. In the United States, ketamine is a class III scheduled drug and is approved for use in hospitals and other medical settings as an anesthetic. “Psychedelics have shown great promise for mental health and wellness, and Kernel’s collaboration with Cybin has the promise of offering increased scientific rigor for their development,” said Kernel founder and CEO Bryan Johnson. Cybin Corp., a leading biotech company focused on progressing psychedelic therapeutics, is on a mission to revolutionize mental health care. The company is focused on progressing psychedelic therapeutics by utilizing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. For more information, visit the company’s website at www.Cybin.com. NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

• Further refinement of if the i/Blue Imaging System will incorporate changes intended to meet critical verification requirements established through benchmark testing of competitive systems as well as feedback from preliminary meetings with the FDA
• Bladder cancer is anticipated to cause over 1,000,000 physician consultations per year, resulting in $4 billion in total costs for bladder cancer treatment and management
• Imagin Medical plans to complete its proprietary i/Blue Imaging System in 2022

The National Cancer Institute (“NCI”) lists urinary bladder cancer as the sixth most prevalent form of cancer in the United States. In 2021, NCI estimates that the total number of new bladder cancer cases will total 83,730, with deaths estimated at 17,200. The recurrence rate for bladder cancer is greater than 50%, making it one of the highest recurrence rates of all cancers. Approximately 724,000 people live in fear that their cancer will return (https://ibn.fm/BST5x). Continuous monitoring of patients who might suffer a recurrence of bladder cancer will generate over 1,000,000 physician consultations per year. These visits add to the $4 billion in costs for bladder cancer management. It is estimated that 25% more tumors are removed using blue light cystoscopy (“BLC”), a more recent technology, that works in conjunction with white light, reducing recurrence and monitoring expenses over the long term. However, the challenges for surgeons with current BLC technology include locating the exact position of the cancer within the bladder. Currently, the surgeon needs to switch back and forth between white light and blue light images, yet still does not have precise visualization. This is one reason that hospitals and doctors have been slow to adopt BLC. Imagin Medical (CSE: IME) (OTCQB: IMEXF) is currently working closely with manufacturing partner Lighthouse Imaging, an FDA-registered and ISO 13485:2016 certified manufacturer, on the company’s proprietary i/Blue Imaging System once per article – it is already above. Their innovative technology will have the ability to display white and blue light images side-by-side simultaneously, providing better visualization and allowing surgeons greater ability to detect and remove cancerous tumors from the bladder. In addition, the technology will adapt to most endoscopes used in the operating room today, enabling easier and cost-effective adoption without requiring hospitals and doctor’s offices to replace their current equipment. In a recent press release, Imagin Medical announced that the i/Blue Imaging System is on target for demonstration during private meetings at the American Urology Association (“AUA”) annual meeting scheduled for early September. The updated product design will incorporate changes intended to meet critical verification requirements established through benchmark testing of competitive systems and feedback from preliminary meetings with the FDA (https://ibn.fm/XscrI). Additional testing and specification development was focused on the contrast agent-induced fluorescence and the ability to replicate the clinical observations in bench-level settings. The sensitivity of the system can now be demonstrated with the established testing methods. “We’re creating the potential for additional IP that will make the i/Blue Imaging System unique and innovative and strengthen the demand for blue light cystoscopy,” said Jim Hutchens, Imagin’s president and CEO. “Patients have been hearing about the superiority of blue light over white light to identify bladder cancer tumors and are searching for facilities that provide it.” Although the primary focus of Imagin Medical is bladder cancer, the company intends to expand the i/Blue Imaging System technology for use in other minimally invasive surgical procedures. The i/Blue Imaging System is expected to be completed in 2022. For more information, visit the company’s website at www.ImaginMedical.com. NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF

• Tryp Therapeutics’ Chairman and CEO Greg McKee will present at the virtual Psychedelics in Psychiatry and Beyond Conference planned for Thursday, June 17, 2021
• As part of his presentation, McKee will discuss Tryp’s business and its pipeline, which includes its proprietary psilocybin-centered drug development program
• Tryp will present alongside other pharmaceutical companies leading research in psychedelic-assisted therapeutics

Psychedelics have increasingly drawn the attention of different players and companies thanks to the research-driven revelations regarding their utility in treating a wide range of neuropsychiatric diseases. As a pharmaceutical company that has been furthering such research – specifically on psilocybin, a psychedelic substance – in order to develop clinical-stage compounds for diseases with high unmet medical needs, Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is the perfect candidate to participate in psychedelics events. In a recent press release (https://ibn.fm/Z8Ify), Tryp announced it would present at one such event: the virtual Psychedelics in Psychiatry and Beyond Conference slated for Thursday, June 17, 2021, and sponsored by H.C. Wainwright & Co., one of America’s oldest and most trusted investment banks focused on equity research and capital market activity. As part of Tryp’s presentation to be made available on-demand from 7 a.m. EDT on the day of the conference, Chairman and CEO Greg McKee will offer insight into the company’s business as well as its research-backed pipeline, including the proprietary Psilocybin-For-Neuropsychiatric Disorders (“PFN”) program. The PFN program is Tryp’s psychedelics-centered drug development platform targeting certain neuropsychiatric disorders, including fibromyalgia, chronic pain, and eating disorders. The program’s lead drug candidate, TRP-8802, is expected to proceed directly to Phase 2a clinical trials as Tryp intends to leverage existing preclinical and clinical data from the expansive body of research on the active pharmaceutical ingredients in TRP-8802. This approach is expected to accelerate the drug development process toward ultimate approval by the US Food and Drug Administration (“FDA”). The company intends to further expand research into other indications for psilocybin that, up until this point, have received little attention from pharmaceutical companies. By collaborating with multiple academic institutions and leading principal investigators, Tryp expects to develop new novel treatments, thereby addressing the significant unmet medical needs. Designed for public and private companies, industry executives, business development executives, venture capitalists, private equity firms, and institutional investors, the conference will feature company presentations, one-on-one investor meetings, and networking opportunities. Attendees should look forward to gaining a deep understanding of psychedelics and the future of this vital class of compounds in psychiatric applications as well as other uses. Tryp will present alongside other leading pharmaceutical companies currently building a robust R&D pipeline of psychedelic-assisted therapeutics. These include Mindset Pharma Inc. (https://ibn.fm/kUTKb) and Mydecine Innovations Group (https://ibn.fm/178sr), among others. To register for the event, attendees can use the following link: https://ibn.fm/5uuv1 For more information, visit the company’s website at www.TrypTherapeutics.com. NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF

• New report cites new management, very good customer ratings and record revenue in initiating CHAL coverage
• Chalice Brands acquisition of Homegrown Oregon also noted
• CHAL’s consistent increase in financial numbers key to BUY rating as well

A recent Fundamental Research Corp. report has initiated coverage of Chalice Brands (CSE: CHAL) (OTCQB: CHALF) with a BUY rating and a fair value estimate of C$2.46 (https://ibn.fm/W7HfD). CHAL closed at C$1.37 on June 8, 2021.  Chalice is a leader in retail, marketing and craft cultivation supported by fully integrated processing and distribution. “New management has demonstrated their ability by significantly growing the company’s revenue and margins in 2020,” the Fundamental Research Corp. report stated. “Another testimonial for the team is that all of their stores have very good customer ratings. We are expecting record revenue in 2021, driven by organic growth and the recent acquisition. We are also expecting a bump in valuations of U.S. cannabis players as the sector moves closer to federal legalization.” As a basis for its BUY rating, the report noted the management overhaul, which includes key team members from Fortune 25 companies and brings experiences from companies such as Microsoft (NASDAQ: MSFT), Kraft Foods (NASDAQ: KHC), Dell (NYSE: DELL), Merrill Lynch and PepsiCo (NASDAQ: PEP) to Chalice. The report also cited the company’s seven retail stores in Oregon, which accounted for 90% of the company’s 2020 revenues. In addition, “the company recently announced it acquired a five-store retail chain, ‘Homegrown Oregon,’ valued at US$9.75M,” the report observed. “Homegrown had $2.7M in revenue and $364K in adjusted EBITDA for the quarter ended March 31, 2021, per management. The implied EV/R of the transaction is 0.9x vs the peer group average of 4x.” The report also pointed to CHAL’s 2020 revenues, which were $22 million, a 39% year-over-year increase through organic growth, as well as the fact that its Q4 2020 numbers noted positive EBITDA. “In Q1 2021, revenue increased 18% YoY to $5.5M,” the report continued. “EBITDA was positive in Q1 2021 as well. In 2021, CHAL raised C$13.75M through private placements.” Finally, the report noted that both the Oregon and California cannabis market saw record sales in 2020, with Oregon reporting $1.1 billion in sales and California posting $4.4 billion in sales, a year-over-year increase of 38% and 57% respectively. “U.S.-based cannabis stocks are currently trading at a discount over their Canadian peers,” the report stated. “We expect this trend to change with federal legalization in the U.S. and anticipate CHAL to directly benefit. We are expecting record revenue for CHAL in 2021. Management is targeting to capture 5% of the Oregon retail cannabis market, which we believe is a feasible target.” Chalice Brands is a premier consumer-driven cannabis company specializing in production, processing, wholesale, distribution and retail, with seven dispensaries in Portland, Oregon. The Company is committed to developing a dynamic portfolio built around the recognized brands of Chalice Farms, with a focus on health and wellness. Chalice operates nationally through Fifth and Root and has operations in Oregon and California. For more information, visit the company’s website at www.ChaliceBrandsLtd.com. NOTE TO INVESTORS: The latest news and updates relating to CHALF are available in the company’s newsroom at https://ibn.fm/CHALF

• Americans pay more for prescription drugs than any other nation in the world; prices keep increasing
• Patients pay about 14% of prescription drug costs out of pockets; around 20% report not being able to complete a prescribed course of medicine due to costs
• UME’s committed to providing consumers better access to the healthcare they need; its Medication Management App features GoodRx in-built functionality enabling them to view discount prices and coupons

United Medical Equipment Business Solutions Network (“UME”) has developed the Medication Management App with twelve different functionalities within the convenience of one application, with the newest addition of GoodRX — a feature that allows users to save money on prescription drugs. Prescription drug spending in the US eclipse that in all other countries — on average $1,200 per person per year — mainly due to high prices of brand-name drugs, which have been increasing faster than the consumer price index (https://ibn.fm/4wdP7). Market exclusivity protected by monopoly rights and patents allows manufacturers to set high drug prices. The prices usually fall after the exclusivity period ends and generic drugs become available, but access to them may be postponed by numerous business and legal tactics. Another contributing factor to high medication spending is doctors prescribing more expensive choices when cheaper alternatives are available. Although high prices are often justified by the high cost of drug research and development, there is no evidence to support this. Instead, prescription drugs are often priced based on what the market will bear. As patients pay about 14% of prescription drug costs out of their own pockets, many are not able to afford the medication bills. A survey found that 20% of US adults could not complete a prescribed course of medicine because of cost, compared to 10% in Germany, Canada, and Australia. UME’s Medication Management App enables users to make quick, well-informed, and potentially lifesaving decision making on the go. The app features an integrated GoodRx function that allows users to view discount prices and coupons while managing medications all within the app. GoodRx, a company allowing users to compare drug prices and find coupons at over 60,000 pharmacies across the US, enables consumers to shop around for prescription drugs and lower their medication costs. Around 20 million people visit GoodRx every month, and over the past decade, the app has helped more than 18 million patients pay for a prescription medication they otherwise would not have been able to afford, saving them around $30 billion to date (https://ibn.fm/3Yfyo). With the help of the GoodRx in-built feature, the UME’s Medication Management App users can compare prices between pharmacies, access free coupons for their prescriptions, and show the coupon to the pharmacist when picking up the prescription — all without ever leaving the app. As US drug manufacturers remain unregulated, which means they can set any price they believe the market will bear for a given drug, the out-of-pocket costs for patients will likely continue to rise. UME strives to be the leading provider of high-quality, reliable, and transparent information and resources for consumers, helping them access the high-quality, affordable healthcare they need. For more information, visit the company’s website at www.UnitedMedSolutions.com. NOTE TO INVESTORS: The latest news and updates relating to United Medical Equipment are available in the company’s newsroom at https://ibn.fm/UnitedMed

• Most extensive research to date reports significant neurological problems in patients who suffered from so-called long-haul COVID-19
• Neurological issues range from mild to more severe such as cognitive impairment, which affects around 20% of these patients
• BRSF appears poised to be part of the solution as long-haulers need monitoring so that doctors can assess if they have neurological disorders

The neurological and psychiatric aftermath of COVID-19 has been reported, but adequately assessing the effects of the disease on brain health still remains a challenge. A new preprint analysis, representing one of the most extensive studies of neuropsychiatric symptoms among COVID-19 long-haulers, reports that patients who have been sick with COVID-19 for more than three weeks experience cognitive impairment at least six months after the infection (https://ibn.fm/OSDQx). Brain Scientific (OTCQB: BRSF), a neurology-focused medical device and software company, is poised to provide brain monitoring capabilities to enable clinicians to study the brain wave activity of patients with neurological conditions. So-called long COVID has gained momentum over the past year as some patients reported persistent neurological and psychiatric manifestations after their initial infection. The extensive research studied nearly 19,000 adult patients across 51 studies, discussing evidence indicating a potential relationship between COVID-19 and persistent neurological problems. These problems could range from milder symptoms, including headaches, loss of sense of smell and taste, and fatigue, to more severe conditions, including sleep disorders, pain, and cognitive impairment such as brain fog leading to memory loss or difficulty concentrating or making decisions. The study found that brain fog affects 20% of Coronavirus long-haulers, while 27% of them reported insomnia, and 24% reported fatigue, both of which researchers believe could stem from neurological issues, although that might not be the only possible cause. Brain fog can have varying impacts on patients; for some, it may be life-altering, while for others can be a minor inconvenience. However, diagnosing long-term COVID-19 symptoms remains a challenge as doctors are still learning the underlying mechanisms of how the virus works. For example, without knowing how long these neurological symptoms last, doctors are not able to classify them as neurological disorders or even chronic illnesses. The researchers conclude that doctors will need to track long-haulers to decipher whether they have neurological disorders after they suffered and survived Coronavirus infection. As a growing body of research indicates, the long-term outlook for COVID-19 patients is still uncertain. Long haul Covid-19 survivors will need ongoing medical help to track and manage the long-term impact of the virus on their health, including brain health. That’s where Brain Scientific’s unique technology can help. The Company has developed NeuroEEG(TM), a portable, wireless device that can record and display the patient’s electrical brain activity that works together with the NeuroCap(TM) — a hospital-grade disposable EEG headset that comes in sizes for adults and pediatric patients.  Brain Scientific is working on developing another revolutionary technology — Brain E-Tattoo(TM), a minimally invasive four-channel implant or imprint tattoo designed for long-term brain wave activity monitoring even beyond the clinical setting. It can provide access to long-term neurological studies, potentially helping identify root neurological problems. More than a year into the pandemic, it remains a challenge to understand the immediate effect of the virus on brain health, with no definite answer regarding the long-term impact either (https://ibn.fm/xNJLl). The scientific world is only starting to truly grasp the effect of COVID-19 on the brain. Brain Scientific appears poised to be a key player providing unparalleled technology that will potentially contribute to providing answers to the most pressing issues in the modern brain diagnostics space. For more information, visit the company’s website at www.BrainScientific.com/Invest-Now. NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF